| __timestamp | Halozyme Therapeutics, Inc. | Insmed Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 22732000 | 33534999 |
| Thursday, January 1, 2015 | 29245000 | 1982000 |
| Friday, January 1, 2016 | 33206000 | 2438000 |
| Sunday, January 1, 2017 | 31152000 | 2901000 |
| Monday, January 1, 2018 | 10136000 | 2423000 |
| Tuesday, January 1, 2019 | 45546000 | 24212000 |
| Wednesday, January 1, 2020 | 43367000 | 39872000 |
| Friday, January 1, 2021 | 81413000 | 44152000 |
| Saturday, January 1, 2022 | 139304000 | 55126000 |
| Sunday, January 1, 2023 | 192361000 | 65573000 |
| Monday, January 1, 2024 | 159417000 |
Unleashing insights
In the competitive landscape of biotechnology, Insmed Incorporated and Halozyme Therapeutics, Inc. have shown distinct trajectories in their cost of revenue over the past decade. From 2014 to 2023, Halozyme's cost of revenue surged by an impressive 747%, peaking at nearly $192 million in 2023. This growth reflects their strategic investments and expanding market presence. In contrast, Insmed's cost of revenue increased by approximately 95% during the same period, reaching around $66 million in 2023. This steady rise underscores Insmed's commitment to innovation and operational efficiency.
The data reveals a pivotal shift in 2021, where Halozyme's cost of revenue began to outpace Insmed's significantly, highlighting their aggressive expansion strategy. As these companies continue to evolve, their financial strategies will be crucial in shaping their future in the biotech industry.
Gilead Sciences, Inc. vs Insmed Incorporated: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Halozyme Therapeutics, Inc.'s Expenses
Cost of Revenue Trends: Neurocrine Biosciences, Inc. vs Halozyme Therapeutics, Inc.
Analyzing Cost of Revenue: Intra-Cellular Therapies, Inc. and Halozyme Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Insmed Incorporated vs Jazz Pharmaceuticals plc
Cost of Revenue Comparison: Insmed Incorporated vs Xenon Pharmaceuticals Inc.
Cost Insights: Breaking Down Jazz Pharmaceuticals plc and Halozyme Therapeutics, Inc.'s Expenses
Halozyme Therapeutics, Inc. vs Grifols, S.A.: Efficiency in Cost of Revenue Explored
Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and MorphoSys AG
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs Wave Life Sciences Ltd.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Viridian Therapeutics, Inc.'s Expenses